The news is part of the organization’s goal of demonstrating a commitment to women’s health.
Stock.adobe.com
Blue Cross Blue Shield of Massachusetts announced a variety of new services focused on providing women and families with necessary health resources and services.1 This announcement is part of an initiative from the organize to demonstrate its commitment to women’s health.
Sarah Iselin, president and CEO of Blue Cross, said that the goal of the initiative is to be the best plan for women’s health in the country. This includes providing support for caregivers, menopause treatments, and other services.
In a press release, Blue Cross’ clinical director of reproductive health and gender affirming services Dr. Monica Ruehli said, “We want our members to feel supported and cared for during every stage of their health journey, from adolescence through maternity, postpartum and menopause. We're proud of the work we're doing to support both our employees and our members, and these new initiatives are just more ways we can help meet the needs of women and families."
As part of the initiative, Blue Cross launched a pilot program with Accompany Doula Care to address racial inequities in maternal and birthing care. Accompany Doula Care’s interim executive director Adwapa Asenso said, “We are proud and excited to be working with Blue Cross, as our goals align in reaching families who may have less access to doula services but stand to benefit from them the most. By providing culturally sensitive, continuous support throughout pregnancy and postpartum, we aim to empower families, improve birth outcomes, and co-build a path forward to increase access and deliver quality care to underserved communities."
Blue Cross also partnered with Maven Clinic for menopause support. The clinic’s chief medical officer Dr. Neel Shah said, “Blue Cross Blue Shield of Massachusetts is a true champion of innovation in the health care system. As early digital health adopters, they have long recognized the power of technology to meet women and families where they are. We are thrilled to extend our work with them to include menopause and midlife health—ensuring that members can find care on the same platform throughout their entire reproductive lifecycle."
Blue Cross Blue Shield of Massachusetts also recently announced the launch of the Health Equity Business Accelerator, which will provide five health start-ups with a one-time grant of $50,000 in 2025.2
In a press release, Blue Cross’ chief financial officer Ruby Kam said, “The Accelerator is an important part of Blue Cross' broader commitment to diversity, equity, inclusion and belonging. We're thrilled to be working with MassChallenge to further strengthen the program and to support organizations developing health care solutions that will have an important impact."
Will Magruder, vice president of partnerships at MassChallenge also said, “We're thrilled to expand our partnership with Blue Cross Blue Shield of Massachusetts to support the next generation of health equity innovators. Through the Health Equity Business Accelerator program, we're providing startups with the tools and resources they need to develop scalable solutions that address critical health disparities. By fostering collaboration and innovation, we're working towards a healthier and more equitable future for all."
Asembia 2025: Therapy Advancements Highlight Growing Cost and Access Concerns
April 30th 2025Fran Gregory, VP, emerging therapies, Cardinal Health, discusses the evolving cell and gene therapy landscape, highlighting pipeline growth, cost challenges, and emerging therapeutic areas beyond oncology and hematology.
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
April 14th 2025LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
FDA Approves AbbVie’s Rinvoq as First Oral JAK Inhibitor for Giant Cell Arteritis
April 30th 2025AbbVie secures FDA approval for Rinvoq as the first oral Janus kinase inhibitor indicated for giant cell arteritis, expanding its immunology portfolio and signaling strategic growth opportunities in underserved autoimmune markets.